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Enteric pathogens have developed several resistance mechanisms to survive the antimicrobial action of bile.
We investigated the transcriptional profile of Vibrio cholerae O1 El Tor strain C6706 under virulence gene-
inducing conditions in the presence and absence of bile. Microarray analysis revealed that the expression of
119 genes was affected by bile. The mRNA levels of genes encoding proteins involved in transport were
increased in the presence of bile, whereas the mRNA levels of genes encoding proteins involved in pathogenesis
and chemotaxis were decreased. This study identified genes encoding transcriptional regulators from the TetR
family (vexR and breR) and multidrug efflux pumps from the resistance-nodulation-cell division superfamily
(vexB and vexD [herein renamed breB]) that were induced in response to bile. Further analysis regarding vexAB
and breAB expression in the presence of various antimicrobial compounds established that vexAB was induced
in the presence of bile, sodium dodecyl sulfate, or novobiocin and that the induction of breAB was specific to
bile. BreR is a direct repressor of the breAB promoter and is able to regulate its own expression, as demon-
strated by transcriptional and electrophoretic mobility shift assays (EMSA). The expression of breR and breAB
is induced in the presence of the bile salts cholate, deoxycholate, and chenodeoxycholate, and EMSA showed
that deoxycholate is able to abolish the formation of BreR-PbreR complexes. We propose that deoxycholate is
able to interact with BreR and induce a conformational change that interferes with the DNA binding ability of
BreR, resulting in breAB and breR expression. These results provide new insight into a transcriptional
regulator and a transport system that likely play essential roles in the ability of V. cholerae to resist the action
of bile in the host.
Pathogenic bacteria continuously monitor environmental
parameters (pH, osmolarity, and temperature) to adapt to
their host and regulate virulence gene expression. The human
gastrointestinal tract can be considered to be an extreme en-
vironment for enteric bacteria where they need to adjust to
stressful conditions, including exposure to bile (2). Bile is a
hepatic secretion that is stored in the gallbladder and is re-
leased into the duodenum. It is composed of bile salts, choles-
terol, phospholipids, antibodies, pigments, and metals, among
other components (20). Bile has the essential role of emulsi-
fying and absorbing lipids from the diet. Moreover, bile aids in
the elimination of toxins and the excretion of metabolic prod-
ucts and has bactericidal properties (20).
Enteric pathogens have developed several resistance mech-
anisms to survive the antimicrobial action of bile (2, 14). The
main mechanism of bile resistance in gram-negative bacteria is
mediated by the expression of multidrug resistance (MDR)
efflux pumps that actively extrude bile out of the cell (14).
MDR transporters belonging to the resistance-nodulation-cell
division (RND) superfamily are distinct from other transport-
ers because they transport a broad variety of compounds, such
as antibiotics, dyes, and detergents, out of the cell (30). They
are localized in the inner membrane and associate with a
periplasmic membrane fusion protein (MFP) and an outer
membrane protein to generate a three-component multidrug
efflux system spanning the cytoplasmic and outer membranes
that can pump toxic compounds out of the cell (30). Pioneering
studies with Escherichia coli have shown that AcrA (an MFP),
AcrB (an RND pump), and TolC (an outer membrane pro-
tein) make up one such three-component multidrug efflux sys-
tem that can pump different substrates such as novobiocin,
erythromycin, sodium dodecyl sulfate (SDS), cholate, taurode-
oxycholate, and decanoate out of the cell (10, 36, 52). The
AcrAB-like efflux system of Salmonella enterica serovar Typhi-
murium (29) and the CmeABC efflux system of Campylobacter
jejuni are other known three-component systems for which bile
salts, among other compounds, are substrates (33, 34). Since
MDR transporters have broad specificities and use proton
motive force, their overproduction can cause the excretion of
intrinsic metabolites and the loss of membrane potential, pro-
cesses that would be detrimental to the survival of the bacterial
cell (13, 30). Therefore, the expression of the majority of the
MDR transporters is tightly controlled (13). The TetR family
members AcrR and CmeR, for example, are the transcrip-
tional repressors of acrAB and cmeABC, respectively (31, 35).
Vibrio cholerae is a gram-negative, curved, rod-shaped en-
teric bacterium that is the causative agent of the severe diar-
rheal disease cholera. This pathogen has developed several
mechanisms to mediate protection against the action of bile:
(i) it increases motility in the presence of bile, which is hypoth-
esized to be important for the bacterium to swim away from
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high concentrations of bile in the lumen, penetrate the mucus
layer, and gain access to the underlying epithelial cells for
colonization (15, 48) (see Fig. 1A); (ii) it induces the formation
of a biofilm, in which the cells are more resistant than nonbio-
film cells to the bactericidal effect of bile (22); (iii) it enhances
the expression of ompU (encoding a small-pore porin) and
decreases the expression of ompT (encoding a large-pore
porin), reducing bile uptake (4, 43, 44); and (iv) it induces the
expression of genes that encode proteins involved in efflux,
such as AcrA (7) and TolC (3), and efflux pumps, such as VceB
(8), VexB, and VexD (4).
The regulation of V. cholerae genes encoding efflux system
components has been described previously only for the vceCAB
operon. This operon is negatively regulated by the protein
encoded by vceR, which is located upstream from vceCAB in a
divergent orientation (8). The regulators for the vexAB or the
vexCD operon, if any, are still unknown.
To further investigate the response of V. cholerae to bile and
begin to define the bile regulon, we performed a microarray
study to investigate the global response of V. cholerae to crude
bile and determined that the expression of 119 genes was
affected in the presence of bile. In particular, we report that
vexB, vexCD (herein renamed breAB), and two genes encoding
regulators belonging to the TetR family were upregulated in
the presence of bile. When vexAB and breAB expression in
response to different antibiotics and detergents was analyzed,
vexAB was induced by exposure to bile, SDS, or novobiocin
whereas the induction of breAB expression was specific for bile.
Given its specificity, we further characterized the regulatory
mechanism of breAB. We identified BreR as the negative reg-
ulator of breAB and established that BreR is also able to
regulate its own expression. Using electrophoretic mobility
shift assays (EMSA), we demonstrated the direct binding of
BreR to the breAB and breR promoters. Furthermore, we
showed that breAB and breR expression was induced in the
presence of cholate, deoxycholate, or chenodeoxycholate and
that deoxycholate was able to disrupt BreR binding to the breR
promoter. These findings support the hypothesis that bile plays
an important role as a host signal for V. cholerae.
MATERIALS AND METHODS
Bacterial strains, plasmids, primers, antimicrobial compounds, and growth
conditions. The V. cholerae and E. coli strains and the plasmids and primers used
in this study are listed in Tables 1 and 2. The strains were grown in Luria-Bertani
(LB) (38) or AKI (23) medium. Antibiotics (Sigma) were used at the following
concentrations (except for induction experiments): ampicillin, 100 g/ml; kana-
mycin, 45 g/ml; polymyxin B, 50 U/ml; streptomycin, 100 g/ml or 1 mg/ml (for
allelic exchange experiments); and tetracycline, 15 g/ml. For PvexRAB-lacZ,
PbreAB-lacZ, and PbreR-lacZ induction experiments, strains were grown in subin-
hibitory concentrations of erythromycin, polymyxin B, novobiocin, sodium cho-
leate (crude bile), sodium taurodeoxycholate, sodium cholate hydrate, sodium
glycochenodeoxycholate, sodium deoxycholate, taurocholic acid sodium salt hy-
drate, sodium chenodeoxycholate, sodium glycocholate hydrate, sodium glycode-
oxycholate, SDS, and Triton X-100 (all from Sigma) as noted below in the
description of the -galactosidase assay methods. Antibiotic stocks were pre-
pared according to the instructions of the antibiotic manufacturer (Sigma), while
detergent stocks were prepared fresh in LB medium and filter sterilized. For
allelic exchange experiments, LB agar contained 40 g of 5-bromo-4-chloro-3-
indolyl--D-galactopyranoside (X-Gal; Gold Biotechnology Inc.)/ml.
RNA isolation, microarray analyses, and statistical evaluations. Three inde-
pendent experiments were performed for the microarray analysis. For each
experiment, RNA was obtained at four different time points and was prepared
for hybridization; therefore, a total of three slides per time point were analyzed.
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant genotype or description Source orreference
Strains
V. cholerae
C6706 str2 El Tor; Smr Laboratory
collection
KSK262 C6706 str2 lacZ3 28
FCM266 KSK262 PvexRAB-lacZ1 This work
FCM164 KSK262 PbreAB-lacZ1 (PvexCD-lacZ1) This work
FCM225 FCM164 vexR1 This work
FCM168 FCM164 breR1 This work
FCM226 FCM164 vexR1 breR1 This work
FCM211 FCM168 pFC33 This work
FCM213 FCM168 pKAS178 This work
FCM158 KSK262 PbreR-lacZ1 This work
FCM191 FCM158 breR1 This work
FCM214 FCM191 pFC33 This work
FCM216 FCM191 pKAS178 This work
E. coli
Origami(DE3) (ara-leu)7697 araD139 lacX74 galE
galK rpsL phoA PvuII phoR F
laclacIqpro gor-522::Tn10 (Tc)
trxB::kan (DE3)
Novagen
FCM184 Origami(DE3) pFC25 Tetr Ampr Kanr This work
Plasmids
pKAS154 pKAS32 derivative; Kanr 27
pKAS178 pBAD33 derivative; Kanr 24
pGKK344 lacZ3 in pKAS154 This work
pGKK346 lacZ in pGKK344 This work
pFC36 PvexRAB-lacZ1 in pGKK346 This work
pFC28 PbreAB-lacZ1 (PvexCD-lacZ1) in pGKK346 This work
pFC27 PbreR-lacZ1 in pGKK346 This work
pFC32 pKAS154 vexR1 This work
pFC3 pKAS154 breR1 This work
pFC33 BreR-His6 construct in pKAS178 This work
pFC25 BreR-His6 construct in pBAD22 This work
TABLE 2. Primers used in this study
Primer
name Nucleotide sequence (5 to 3)
AAP....................GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG
AP. . ...................GGCCACGCGTCGACTAGTAC(T)17
AUAP ................GGCCACGCGTCGACTAGTAC
CHR2.................GATCGGAATTCGACCGCCACCAAACACTAAG
CHR4.................GATCGGCGGCCGCTCTAGAATGCTAACGATTTTTAGAAC
FC13F ................GATCGGGATCCCGTAAGCAATCTCGCTACTG
FC13R................GATCGGCGGCCGCAGAAGGATTCATAGTGTGTTG
FC18F ................GATCGGAATTCACCATGAAACTCAGTGAGCAAAA
FC18R ..............GATCGTCTAGACTAGTGGTGGTGGTGGTGGTGAGGCTTTAGTTCT
FC25...................CGATAATCTGAGTGTCTGCT
FC24...................AGCAGACACTCAGATTATCG
FC32...................ATGGCATTCAGGGATCAGAA
FC33...................TTCTGATCCCTGAATGCCAT
FC42R................GATCGGAATTCAGCGAGTTACCAATTGGGTTTCG
FC49...................TGGGAGCCACTTCTTTCTCAATCAG
FC50...................CGCAGTCAGCGCCGTATCTTGAG
FC51...................GCTGGATCGCGCACAAATTC
FC57...................GATCGGCGGCCGCTTCAGACATCACATTTCTCTG
FC62...................GATCGTCTAGAGTAACGCGAGCTGATCTTGGT
FC63...................GATCGTCTAGATTCAGACATCACATTTCTCTG
FC72...................GGTCGTAGCGATTGGTGACTTTATCCAG
FC73...................AAATGGCTTTGGCGCGGCGGTACTCTTGTT
FC74...................TTCCAGCGCCGTTTTGGCATCTCG
GAL1 .................GATCGGCGGCCGCGCCAGAGAGCCTTAAGGCTC
GAL2 .................GATCGGGATCCACGCCAACGAGGTAAAAACG
TetB ...................GATCGGGATCCTTTCACGGCGAGCAATGGTGG
TetE ...................GATCGGAATTCGTAACGCGAGCTGATCTTGGT
TetN2 .................GATCGGCGGCCGCACAACACTAATTTGGAGTTCGC
TR3B..................GATCGGGATCCTAATCGCGGCAACCCAGCCAA
TR3E..................GATCGGAATTCCGATTGAATCGACGTTGATCC
TR3N1 ...............GATCGGCGGCCGCGATCCATATTCGCTGCATGGA
TR3N2 ...............GATCGGCGGCCGCAAAGCCTTAGAGGCTAACGGAT
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The growth conditions were as follows: V. cholerae C6706 str2 was grown for 15 h
in LB medium at 30°C with aeration. The cultures were subsequently diluted
100-fold in AKI medium with or without 0.4% crude bile (high bile concentra-
tion) and were grown at 37°C for 3.5 h under stationary conditions and then for
2 h with aeration to induce virulence gene expression (23). Next, the cultures
were diluted 100-fold in AKI medium with or without 0.02% crude bile (low bile
concentration) and were grown at 37°C for 2 h under stationary conditions.
Samples were obtained at four different time points: 2, 4, and 5.5 h for the
high-bile-concentration cultures and 2 h for the low-bile-concentration cultures
(Fig. 1B). RNA isolation, cDNA probe labeling, microarray hybridization, data
detection, and statistical analyses were carried out as described previously (24).
Construction of in-frame deletion strains. Deletions were achieved by the
PCR amplification of 500-bp C6706 str2 DNA fragments flanking the gene of
interest while retaining several codons from the 5 and 3 ends of the gene fused
in frame. The fragments were ligated into pKAS154 (27), and the genes of
interest were deleted from the V. cholerae chromosome by allelic exchange (49).
vexR was deleted using primers TetB with TetN2 and FC57 with TetE, and breR
was deleted using primers TR3B with TR3N2 and TR3N1 with TR3E. The
accuracy of all the constructs was confirmed by DNA sequencing.
Construction of PvexRAB-lacZ, PbreAB-lacZ, and PbreR-lacZ fusions. The lacZ
plasmid pGKK344 was constructed by PCR amplification of two 600-bp frag-
ments flanking the lacZ gene from C6706 str2 by using primers CHR2 with
CHR4 and GAL1 with GAL2. The fragments were joined at a NotI site and
ligated into pKAS154 by using the EcoRI and BamHI sites. The pGKK344
plasmid was linearized with NotI, and a promotorless lacZ gene from pVC200
(40) was ligated into pGKK344, generating pGKK346. After being screened for
the correct orientation of lacZ, pGKK346 was linearized with XbaI between the
chromate homology fragment and the promotorless lacZ gene. Approximately
500 bp of the vexRAB, breAB, or breR promoter region was amplified by PCR
using FC62 with FC63, TR3E with TR3N1, or FC13F with FC13R, respectively.
The resulting fragments from the vexRAB, breAB, and breR promoters were
digested and ligated into the linearized pGKK346 plasmid, generating pFC36,
pFC28, and pFC27, respectively. The lacZ fusions were transferred into the
chromosome of a V. cholerae lacZ strain by allelic exchange (49) between the
chr and gal loci. The accuracy of all the constructs was confirmed by DNA
sequencing.
-Galactosidase assays. Different V. cholerae strains harboring the PvexRAB-
lacZ, PbreAB-lacZ, or PbreR-lacZ transcriptional fusion were grown for 15 h in LB
medium at 37°C with aeration. The cultures were then diluted 100-fold in LB
medium with or without one of the following compounds: crude bile (0.4%),
taurodeoxycholate (300 M), cholate (300 M), glycochenodeoxycholate (300
M), deoxycholate (300 M), taurocholate (300 M), chenodeoxycholate (300
M), glycocholate (300 M), glycodeoxycholate (300 M), SDS (300 M),
Triton X-100 (150 g/ml), erythromycin (0.1 M), novobiocin (0.1 M), or
polymyxin B (5 U/ml). The cultures were grown at 37°C with aeration until the
optical density at 600 nm (OD600) reached 0.8 to 1.0. -Galactosidase assays
were carried out as described previously (38). Prism software was used for all
statistics. P values were calculated using a nonparametric Student two-tailed t
test. P values of 	0.05 were considered statistically significant throughout.
Construction of expression plasmid. The expression plasmid generated for
this study is listed in Table 1. A His6 tag was fused to the C terminus of BreR by
amplifying the breR gene from C6706 str2 with primers FC18F and FC18R. The
resulting fragment was ligated into pBAD22 (16), generating pFC25. E. coli was
transformed with the pFC25 plasmid by electroporation for BreR purification.
The accuracy of the construct was confirmed by DNA sequencing.
Identification of the breAB and breR transcriptional start sites. The C6706 str2
strain was grown for 15 h in LB medium at 37°C with aeration. The culture was
then diluted 100-fold in LB medium in the presence of crude bile and was grown
at 37°C with aeration until the OD600 of the culture had reached 0.8 to 1.0. Total
RNA was isolated as described previously (24) and subjected to 5 rapid ampli-
fication of cDNA ends (5 RACE) (11) according to the protocols of the 5
RACE kit manufacturer (Invitrogen). Briefly, first-strand cDNA synthesis was
carried out using 1 g of RNA, reverse transcriptase, and either the breA-specific
primer FC72 or the breR-specific primer FC49. The cDNA was purified using a
PCR purification kit (Qiagen), and poly(dC) or poly(dA) tails were added to the
3 ends using terminal deoxynucleotidyltransferase. Prior to nested amplifica-
tions, second-strand cDNA synthesis was necessary for the poly(dA)-tailed
cDNA and was carried out using the 3 RACE adapter primer. PCR amplifica-
tion of the cDNA was carried out using the 5 RACE abridged anchor primer
with the first nested primer FC73 (breA) for the poly(dC)-tailed cDNA or the
abridged universal amplification primer (AUAP) with the first nested primer
FC50 (breR) for the poly(dA)-tailed cDNA. A dilution of the PCR mixture was
subjected to reamplification using the AUAP with the second nested primer
FC74 (breA) for the poly(dC)-tailed cDNA or the AUAP with the second nested
primer FC51 (breR) for the poly(dA)-tailed cDNA. The DNA products were
then run on an agarose gel, gel extracted (Qiagen), and sequenced.
Purification of BreR-His6. E. coli Origami(DE3) (Novagen) carrying plasmid
pFC25 was grown overnight at 37°C with aeration. The culture was diluted
100-fold in LB medium containing kanamycin, tetracycline, and ampicillin,
grown to an OD600 of 0.6 at 37°C, and induced with 0.1% arabinose, with
incubation for an additional 2 h. The cells were harvested by centrifugation and
resuspended in buffer A (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 1
mM phenylmethylsulfonyl fluoride, pH 7.0). The suspension was sonicated and
centrifuged at 14,000 rpm in a microcentrifuge at 4°C for 20 min. The superna-
tant was then collected. A column containing Talon metal affinity resin (Clon-
tech) was preequilibrated with buffer B (50 mM NaH2PO4, 300 mM NaCl, pH
7.0). The column was loaded with the supernatant containing BreR-His6 and
washed with buffer C (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH
7.0), and BreR-His6 was eluted with buffer D (50 mM NaH2PO4, 300 mM NaCl,
250 mM imidazole, pH 7.0). Fractions were collected and analyzed by SDS-
polyacrylamide gel electrophoresis (PAGE). Those containing BreR-His6 were
pooled and dialyzed overnight in binding buffer [20 mM HEPES (pH 7.6), 1 mM
EDTA, 10 mM (NH4)2SO4, 5 mM dithiothreitol, 0.2% Tween 20, 30 mM KCl]
(31). BreR-His6 purity was estimated by SDS-PAGE to be 90% (data not
shown). Glycerol was added to purified BreR-His6 to a 10% (vol/vol) final
concentration before storage at 
80°C.
EMSA. The fragments designated AB1 (the nucleotide sequence between 
95
and 132 of the breAB promoter region), AB2 (
382 to 
76 of the breAB
promoter region), and AB2s (
382 to 
95 of the breAB promoter region) were
amplified from pFC28 using FC24 with FC13R, FC13F with FC25, and FC13F
with FC42R, respectively. The fragments R1 (
102 to 131 of the breR pro-
moter region) and R2 (
370 to
83 of the breR promoter region) were amplified
from pFC27 using TR3N1 with FC33 and FC32 with TR3E, respectively. The
penicillin V amidase (PVA) gene fragment (18 to 191 of the pva promoter)
was obtained by PCR as described previously (25). The fragments were gel
purified and 3 end labeled with digoxigenin (DIG) as described previously (26).
Reactions for binding BreR-His6 with the different fragments and the electro-
phoresis of these samples in a 6% polyacrylamide gel were carried out as de-
scribed previously (31). For the BreR binding inhibition experiment, 5, 10, 20, 40,
or 80 mM deoxycholate, 10 mM glycocholate, or 10 mM glycodeoxycholate was
incubated with BreR for 15 min at 37°C prior to the addition of the R1 fragment.
The DNA was transferred, probed, and detected as described previously (24).
Susceptibility tests. The minimal bactericidal concentration (MBC) of crude
bile was determined using a modified microtiter dilution method as described
previously (31). Briefly, wild-type, breAB, and breR strains were grown in LB
medium with aeration at 30°C for 15 h. The cultures were then diluted in LB to
obtain stocks with a cell density of5 105 CFU/ml. A microtiter plate was used
for each antimicrobial compound, which was diluted in a 1.5-fold series. Each
well was inoculated, in duplicate, with 10 l of each strain stock. The final volume
for each well was 100 l, and the final bacterial density was 5  104 CFU/ml.
The microtiter plates were incubated at 37°C with aeration (180 rpm) for 6 h.
Finally, 10 l of culture from each well was spotted onto LB agar by using a
multichannel pipette, and the agar was incubated overnight at 30°C to determine
the MBC.
Microarray data accession number. The microarray data discussed herein
have been deposited in the NCBI Gene Expression Omnibus (GEO; http://www
.ncbi.nlm.nih.gov/geo/) and are accessible through GEO series accession number
GSE6468.
RESULTS
Global gene expression in V. cholerae in response to crude
bile. Studies with V. cholerae have shown that in the presence
of bile the expression of virulence genes is repressed and mo-
tility and/or chemotaxis is increased (15, 48). From these stud-
ies, Schuhmacher and Klose formulated a model hypothesizing
the effect of bile on colonization: they propose that bile is at a
higher concentration in the intestinal lumen than in the mucus
layer (48). When the bacterium is within the lumen, bile in-
hibits the transcription of the virulence genes and induces
motility and/or chemotaxis to mobilize the bacterium into the
mucus layer. Upon migration through this layer, there is a
derepression of virulence gene expression and the colonization
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of the epithelial cells takes place (Fig. 1A). We investigated
the coordinated response of V. cholerae gene expression to the
presence of crude bile by using a microarray analysis. The
proposed in vivo conditions were simulated by growing V.
cholerae O1 El Tor strain C6706 str2 under virulence gene-
inducing conditions (in AKI medium) in vitro in the presence
of a high bile concentration (0.4% crude bile) for 5.5 h and
then diluting the cultures (100-fold) in AKI medium in the
presence of a low bile concentration (0.02% crude bile) for 2 h
(Fig. 1). Since the effect of bile on V. cholerae has been deter-
mined previously using 0.4% crude bile (15, 21, 22, 48), a
concentration within the estimated range of concentrations of
individual bile salts in the intestine (0.2 to 2%) (20), we utilized
this concentration as the high bile concentration, whereas
0.02% crude bile was employed as the low bile concentration
because it was 10-fold lower than the lowest individual bile salt
concentration in the intestine (0.2%) (20). Samples were ob-
tained at 2, 4, and 5.5 h from the high-bile cultures and at 2 h
from the low-bile cultures (Fig. 1B). The same scheme was
followed for the reference cultures grown without bile. RNA
was extracted, reverse transcription was performed, and cDNA
from control and bile-treated samples was used for microarray
analysis. A 2-fold change in the mRNA level in high-bile
cultures at two or more of the three time points and the reverse
trend in the low-bile cultures were used as the criteria to
indicate genes for which expression was affected by bile. By
these criteria, a total of 119 genes were found to be differen-
tially expressed in the presence and absence of bile. Forty-eight
genes showed an increase in the RNA level, while 71 genes
showed a decrease. Figure 2 shows the distribution of the
corresponding gene products within cluster of orthologous
group classifications (from the TIGR genome database). The
majority of the genes that showed an increase in the RNA level
and encode products with assigned functions belong to the
group encoding transport and binding proteins (14 genes),
whereas the majority of those that displayed a decrease in the
RNA level encode products that belong to the cellular pro-
cesses category (19 genes in total, 8 being part of the patho-
genesis subset and 11 belonging to the chemotaxis and motility
subset) (Fig. 2; see also Tables S1 and S2 in the supplemental
material). The pathogenesis genes tcpA, ctxA, and ctxB showed
a decrease in the mRNA level in the presence of the high bile
concentration, consistent with previous findings (15, 48), and
reversed this decrease in the presence of the low bile concen-
tration, consistent with the hypothesis of Schuhmacher and
Klose (48). The same pattern was observed for the following
genes: tcpQ, tcpD, tcpS, pspA, and hlyA (see Table S2 in the
supplemental material). Studies with the OmpU and OmpT
porins have demonstrated previously that ompU transcription
is stimulated in the presence of crude bile or deoxycholate (44)
and that the expression of ompT is repressed (4). Neither
ompU nor ompT mRNA was identified as being affected by bile
by our criteria. However, the ompT mRNA level in the pres-
ence of the high bile concentration was decreased 24-fold com-
pared to the baseline level at the 5.5-h time point, and this
trend was reverted in the presence of the low bile concentra-
tion, although we did not detect changes in ompU mRNA
levels at any of the different time points. None of the genes
involved in biofilm formation in the presence of bile (vps genes
and vpsR) (22) were identified using our criteria. This outcome
was anticipated, though, since our experimental conditions did
not promote biofilm formation. The vexB and vexD genes,
encoding efflux components that have been shown previously
to play a role in resistance to deoxycholate and other com-
pounds (4), and the vexC gene, encoding a putative MFP,
showed an increase in the mRNA level in the presence of a
high bile concentration and reversed this increase under the
low-bile conditions (see Table S1 in the supplemental mate-
rial). Using our criteria, we did not identify the vceA, vceB, or
vexA gene, encoding an MFP, a multidrug efflux pump, and a
putative MFP, respectively, as being affected by bile, even
though these genes encode proteins involved in bile resistance
(4, 8). However, vceA and vexA showed three- and twofold
increases in the mRNA level, respectively, only in the presence
of the high bile concentration at the 5.5-h time point, and this
trend was reverted in the presence of the low bile concentra-
tion. In addition, three genes, vexR, VC1746, and VCA0933,
classified as having regulatory functions, showed an increase in
the mRNA level in the presence of the high bile concentration
and a reversion of this trend in the presence of the low bile
concentration (see Table S1 in the supplemental material).
Since the aim of this study was to identify genes for which
expression is affected by bile and genes encoding proteins
involved in the regulation of these genes in response to bile, we
FIG. 1. (A) Model illustrating the effect of bile on V. cholerae
colonization based on a hypothesis proposed by Schuhmacher and
Klose (48). When V. cholerae is within the lumen of the intestine, the
high bile concentration inhibits the transcription of the virulence genes
and induces motility and/or chemotaxis to mobilize the bacterium into
the mucus layer. Upon migration through the mucus layer, where the
bile concentration is low, motility and/or chemotaxis is inhibited and
virulence gene expression is induced, facilitating the colonization of
the epithelial cells by V. cholerae. (B) Schematic representation of the
microarray experimental design.
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further explored the expression of vexAB and vexCD to deter-
mine their response specificities.
The expression of vexAB can be induced by structurally and
chemically unrelated compounds, whereas vexCD expression is
induced exclusively by bile. The vexB and vexD genes encode
efflux pumps belonging to the RND superfamily, while the
vexA and vexC genes each encode an MFP (4). In E. coli (36),
C. jejuni (32), Neisseria gonorrhoeae (46), Pseudomonas aerugi-
nosa (37), and Pseudomonas putida (50), the expression of
genes that encode RND efflux pumps is induced by the differ-
ent substrates extruded by the products of these genes. Bina et
al. demonstrated that bile increases the mRNA levels of the
vexB and vexD transcripts (4). Additionally, after a thorough
study testing several antibiotics, detergents, and metals, it was
shown previously that a vexB mutant is susceptible to structur-
ally dissimilar compounds: SDS, Triton X-100, erythromycin,
novobiocin, polymyxin B, and deoxycholate. This study also
showed that a vexD mutant is susceptible only to deoxycholate
(4). Therefore, we used these compounds to further determine
the specific transcriptional induction of the efflux pump-encod-
ing genes. The expression of vexAB and vexCD was examined
using strains containing lacZ fusions integrated elsewhere in
the chromosome so as not to interfere with the resistance to
the compound being tested. A promotorless lacZ gene was
fused to either 520 bp of DNA upstream of vexR codon 3 or
520 bp of DNA upstream of vexC codon 4, generating the
PvexRAB-lacZ or PvexCD-lacZ fusion, respectively (Fig. 3A and
B). The specific -galactosidase activities from strains grown in
the presence or absence of subinhibitory concentrations of the
compounds mentioned above were measured. Exposure to
crude bile, SDS, and novobiocin induced the expression of
vexAB between 2.2- and 4.3-fold (Fig. 4A), whereas vexCD
expression was induced exclusively by bile, with a 10-fold in-
crease (Fig. 4B). Similar induction results were obtained with
strains harboring lacZ fusions to the wild-type promoter of the
vexRAB or vexCD operon constructed by the insertion/deletion
of lacZ at the vexR or vexC locus, respectively (data not shown).
Overall, these results suggest that the vexCD operon responds
specifically to bile. Therefore, we renamed this operon breAB
for bile response genes and continued to characterize its ex-
pression and identify regulatory proteins associated with it.
BreR represses the expression of the breAB operon. Genes
encoding efflux pumps from the RND family are usually reg-
ulated by TetR family members (30). From the microarray
data, we identified two genes, vexR and VC1746 (see Table S1
in the supplemental material), that encode regulators belong-
ing to the TetR family as determined by BLASTP. We hypoth-
esized that vexR and/or VC1746 may regulate breAB expression
in response to bile. In order to test this hypothesis, we deleted
vexR, VC1746, or both genes in the strain harboring the PbreAB-
lacZ fusion at the lacZ locus. The results showed that the vexR
deletion did not affect lacZ expression, either in the absence or
the presence of 0.4% crude bile (Fig. 5). In contrast, the de-
letion of VC1746 increased lacZ expression 24.5- and 2.8-fold
in the absence and in the presence of crude bile, respectively,
compared to that in the wild type (Fig. 5). These results indi-
cated that VC1746 deletion caused the derepression of PbreAB-
lacZ expression and the loss of the majority of bile responsive-
FIG. 2. Distribution of V. cholerae El Tor genes differentially expressed in response to crude bile as classified within clusters of orthologous
groups assigned by the TIGR database.
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ness, suggesting that VC1746 encodes a bile-responsive
repressor. Finally, the vexR VC1746 double mutant showed an
induction pattern that was the same as that associated with the
VC1746 single deletion (Fig. 5). Since the results (including
those discussed below) indicated that VC1746 encodes a tran-
scriptional repressor of the breAB operon, VC1746 was named
breR. Further analysis using the TIGR database showed that
the protein encoded by breR is composed of 209 amino acids
and has a predicted helix-turn-helix DNA binding motif near
its N terminus, characteristic of transcriptional regulators in
the TetR family (45).
BreR binds to the breAB promoter region. To determine if
BreR directly interacts with the breAB promoter region, we
initially determined the breAB transcriptional start site. 5
RACE (11) determined that the 1 nucleotide of the breAB
promoter is an A located 121 bp upstream of the predicted
FIG. 3. Diagrams showing the promoter regions and fragments employed to generate lacZ transcriptional fusions and DIG-dUTP-labeled
fragments. (A) Fragment of 520 bp from the upstream region of the putative vexAB ATG start codon. (B) breAB (vexCD) promoter region.
Fragments AB1 and AB2 were used for EMSA. (C) breR promoter region. The R1 and R2 fragments were used for EMSA. The breAB and
breR transcriptional start sites are indicated by gray arrows.
FIG. 4. Induction of PvexRAB-lacZ (A) and PvexCD-lacZ (PbreAB-
lacZ) (B) expression by different compounds. -Galactosidase expres-
sion was measured by growing the strains in the absence or presence of
subinhibitory concentrations of crude bile (0.4%), SDS (300 M),
Triton X-100 (150 g/ml), erythromycin (0.1 M), novobiocin (0.1
M), or polymyxin B (5 U/ml) in LB at 37°C until the OD600 of the
cultures reached 0.8 to 1.0. The amount of change (n-fold) in -galac-
tosidase activity was calculated by dividing the level of -galactosidase
activity obtained in the presence of each compound by the activity
obtained in the absence of the compound. The results shown are from
three independent experiments. Error bars indicate standard devia-
tions.
FIG. 5. Induction of PbreAB-lacZ expression in various strain back-
grounds by crude bile. -Galactosidase expression was measured by
growing the strains in the absence or presence of 0.4% crude bile in LB
at 37°C until the OD600 of the cultures reached 0.8 to 1.0. The results
shown are from three independent experiments. Error bars indicate
standard deviations.
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breA ATG start codon (Fig. 6A). Further examination of the
upstream region revealed the presence of putative 
35
(TTTACT) and 
10 (TATGAT) regions (Fig. 6A) separated
by 18 bp. The 
35 sequence has two mismatches from the
consensus sequence TTGACA, and the 
10 sequence has only
one mismatch from the consensus sequence TATAAT.
Subsequently, EMSA was performed using a purified BreR-
His6 fusion protein. BreR-His6 was overexpressed from pFC25
in E. coli Origami(DE3) (Novagen) and purified by nickel-
nitrilotriacetic acid affinity column chromatography to approx-
imately 90% purity as judged by SDS-PAGE on a gel stained
with Coomassie blue. The apparent molecular mass of purified
BreR-His6 is 23 kDa, consistent with the predicted size (data
not shown). The breAB promoter region utilized for the lacZ
transcriptional fusions was divided into two slightly overlap-
ping fragments, an 230-bp fragment (the nucleotide se-
quence between 
95 and 132) named AB1 and an 300-bp
fragment (
382 to 
76) named AB2 (Fig. 3B). In addition, an
175-bp fragment from the unrelated PVA gene (pva) pro-
moter (the PVA fragment) (25) was utilized as a negative
control. BreR-His6 was incubated with the AB1, AB2, or PVA
fragment in the presence of poly(dI-dC) and, surprisingly,
caused a mobility shift of both the AB1 and AB2 fragments at
low (50-ng) and high (250-ng) protein levels (Fig. 6B, lanes 5,
6, 8, and 9), whereas no shift of the PVA control fragment was
observed (Fig. 6B, lanes 2 and 3). These data provide evidence
for the direct binding of BreR to the breAB promoter region.
Furthermore, they suggest that BreR binds the breAB pro-
moter at two independent sites. However, the AB1 and AB2
fragments overlap by 20 bp, and this may account for BreR’s
binding of both fragments. Therefore, an 280-bp fragment
(
382 to 
95) named AB2s was designed (see Fig. S1A in the
supplemental material). The AB1, AB2s, and PVA fragments
were incubated with BreR-His6, and a mobility shift was ob-
served with both the AB1 and AB2s fragments (see Fig. S1B in
the supplemental material), thus demonstrating the ability of
BreR to bind to the breAB promoter at two independent sites,
one distal from the 1 site (within AB2 or AB2s) and one
proximal (within AB1).
Expression of breR is induced in response to bile in a BreR-
dependent manner. To analyze the regulation of breR expres-
sion, we used a PbreR-lacZ transcriptional fusion. We designed
a reporter strain containing the wild-type breR operon and
500 bp of DNA upstream of breR codon 30 fused to a pro-
motorless lacZ gene and integrated into the V. cholerae chro-
mosome at the lacZ locus (Fig. 3C). The transcription of the
PbreR-lacZ fusion was increased 6.6-fold when the strain was
grown in the presence of crude bile (Fig. 7). Similar induction
was obtained with strains harboring lacZ fusions to the wild-
type promoter of the breR operon constructed by the insertion/
deletion of lacZ at the breR locus (data not shown).
Several transcriptional regulators from the TetR family,
such as TetR, AcrR, UidR, and MexR, negatively regulate
their own expression (5, 18, 35, 41). To investigate if breR is
subject to autoregulation, we generated a breR deletion deriv-
ative of the reporter strain harboring the PbreR-lacZ fusion at
the lacZ locus. The deletion of breR led to 13- and 2.4-fold
increases in lacZ expression in the absence and presence of
FIG. 6. Specific binding of BreR to the breAB promoter region. (A) Nucleotide sequence of the breAB promoter. The position of the
transcriptional start site for breAB was determined by 5 RACE. The transcriptional start site (1), ATG start codon, and putative 
35 and 
10
regions are boldfaced and underlined. (B) EMSA was performed with the control DNA fragment from the pva promoter (25) (lanes 1 to 3) or
the breAB promoter fragments AB1 and AB2 (lanes 4 to 9). DIG-dUTP-labeled DNA (10 ng) was incubated with 0 ng (lanes 1, 4, and 7), 50 ng
(lanes 2, 5, and 8), or 250 ng (lanes 3, 6, and 9) of BreR-His6 prior to electrophoresis. 
, no BreR.
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crude bile, respectively, compared to the expression in the
wild-type background (Fig. 7).
BreR binds to the breR promoter region. To study the po-
tential interaction of BreR with the breR promoter, the tran-
scriptional start site at the breR promoter was first identified.
By using 5 RACE, it was determined that the 1 nucleotide
of the breR promoter is a G located 40 bp upstream of the
predicted ATG start codon (Fig. 8A). The inspection of the
upstream region revealed a putative 
35 (TGTACT) region
with three mismatches from the consensus sequence TTGACA
and a putative 
10 (TATAGT) region with only one mismatch
from the consensus sequence TATAAT. The putative 
35 and

10 sequences (Fig. 8A) are separated by 17 bp.
Consequently, EMSA was performed utilizing BreR-His6
and two fragments: a 230-bp fragment (
102 to 131)
named R1 and a 290-bp fragment (
370 to 
83) named R2
obtained from the division of the breR promoter region used
for the lacZ fusions (Fig. 3C). The results showed that after the
incubation of BreR-His6 with the R1, R2, or PVA (negative
control) fragment, BreR bound only to the R1 fragment (Fig.
8B, lanes 8 and 9) and not to the R2 or PVA fragment (Fig. 8B,
lanes 2, 3, 5, and 6). Given that no supershift was observed with
the R1 fragment in the presence of BreR, it is highly probable
that BreR binds at only one site at this promoter. From these
data, we can conclude that BreR binds differently at the breR
promoter and the breAB promoter (Fig. 7), utilizing a single
binding region for the former and two for the latter.
Cholate, deoxycholate, and chenodeoxycholate are inducers
of breAB and breR expression. Since bile salts are abundant
components of crude bile (2, 20), we tested individual bile salts
to determine if any could induce breAB and/or breR expression.
The reporter strains harboring the PbreAB-lacZ or the PbreR-
lacZ fusion at the lacZ locus were grown in the presence of a
subinhibitory concentration (300 M) of eight different bile
salts. The expression of PbreAB-lacZ and PbreR-lacZ was signif-
icantly induced (P	 0.05) in the presence of deoxycholate (17-
and 5-fold, respectively) and chenodeoxycholate (10- and
4-fold, respectively) (Fig. 9A), whereas cholate produced lower-
level inductions of the expression of breAB (3-fold) and breR
(1.4-fold) (Fig. 9A). These results demonstrate that the induc-
tion of breAB and breR expression can be accomplished by the
specific bile salts cholate, deoxycholate, and chenodeoxy-
cholate and that the hierarchy of stronger to weaker inducers
is as follows: deoxycholate  chenodeoxycholate  cholate. To
determine if the response to individual bile salts was also
mediated through BreR, we examined the expression of the
breAB and breR promoters in a breR background with and
FIG. 7. Induction of PbreR-lacZ expression by crude bile and breR
autoregulation. -Galactosidase activity was measured by growing the
strains in the absence or presence of 0.4% crude bile in LB at 37°C
until the OD600 of the cultures reached 0.8 to 1.0. The results shown
are from three independent experiments. Error bars indicate standard
deviations. wt, wild type.
FIG. 8. BreR interaction with the breR promoter region. (A) The breR promoter nucleotide sequence is shown. 5 RACE was utilized to
determine the position of the transcriptional start site for breR. The transcriptional start site (1), ATG start codon, and putative 
35 and 
10
regions are boldfaced and underlined. (B) EMSA was performed with the control DNA fragment from the pva promoter (25) (lanes 1 to 3) or
the breR promoter fragments R1 and R2 (lanes 4 to 9). In the DNA binding assay, the DIG-dUTP-labeled DNA (10 ng) was incubated with 0 ng
(lanes 1, 4, and 7), 50 ng (lanes 2, 5, and 8), or 250 ng (lanes 3, 6, and 9) of BreR-His6.
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without subinhibitory concentrations of cholate, deoxycholate,
chenodeoxycholate, and glycocholate (negative control). The
deletion of breR led to constitutive expression of PbreAB-lacZ
and PbreR-lacZ (Fig. 9B) in the absence and presence of the
different compounds tested.
Deoxycholate inhibits the binding of BreR to the breR pro-
moter. It has been shown previously that the tetracycline re-
pressor (TetR) binds to the tetA operator in the absence of
tetracycline, repressing the expression of tetA, which encodes
an efflux pump. When tetracycline enters the cytoplasm, it
binds to TetR, inducing a conformational change that dissoci-
ates TetR from the tetA operator, allowing the production of
TetA and the active efflux of tetracycline (18, 19). This general
regulatory mechanism has also been described previously for
several members of the TetR family (6, 9, 12, 31, 39, 47, 51).
Given that cholate, deoxycholate, and chenodeoxycholate in-
duce breAB and breR expression, we hypothesized that these
bile salts may interact with BreR. To test this possibility, we
performed EMSA with the R1 fragment and BreR in the
presence of deoxycholate because this bile salt gives the most
robust induction of PbreR-lacZ expression (Fig. 9A). In addi-
tion, we tested BreR binding in the presence of glycocholate, a
noninducing bile salt, and glycodeoxycholate, a noninducing
bile salt with structural similarity to deoxycholate. Initially, we
determined the concentration at which deoxycholate abolished
the formation of the BreR-R1 complex (Fig. 10A). The result
showed that in the presence of 10 mM deoxycholate, BreR
was unable to bind to R1. We selected 10 mM deoxycholate as
the concentration to be used in our binding assay given that it
was the lowest concentration at which we observed the inhibi-
tion of binding. In addition, we used 10 mM glycodeoxycholate
and glycocholate as control bile salts. Figure 10B shows that 10
mM deoxycholate abolished the formation of the BreR-R1
complex but that the same concentration of glycodeoxycholate
or glycocholate did not disrupt this interaction. These results
suggest that deoxycholate is able to specifically prevent the
formation of the BreR-R1 complex.
DISCUSSION
In the present study, we investigated the mechanism of tran-
scriptional activation of genes that encode components in-
volved in facilitating the resistance of V. cholerae to bile. We
initially used microarray technology to investigate the changes
in V. cholerae global gene expression during growth in the
presence of different bile concentrations. The results con-
firmed the repression of the virulence regulon and the induc-
tion of the vexB and breAB (vexCD) genes, which encode efflux
system components. Furthermore, they revealed the induction
FIG. 9. Influence of different bile salts on the expression of PbreAB-
lacZ and PbreR-lacZ as determined by -galactosidase assays. Strains
carrying the PbreR-lacZ or the PbreAB-lacZ fusion were grown in LB in
the absence or presence of a subinhibitory concentration (300 M) of
different bile salts at 37°C until the OD600 of the cultures reached 0.8
to 1.0. The results shown are from three independent experiments.
Error bars indicate standard deviations. Asterisks indicate statistically
significant differences from the LB control. (A) Induction of PbreAB-
lacZ and PbreR-lacZ fusions in the presence of different bile salts.
(B) Expression of PbreAB-lacZ and PbreR-lacZ in a breR background in
response to different bile salts.
FIG. 10. Effect of deoxycholate on the DNA binding activity of
BreR. (A) Titration of deoxycholate (DOC) to determine the concen-
tration that prevents the formation of BreR-R1 complexes. EMSA was
performed with the R1 fragment and 25 ng of BreR-His6. DIG-dUTP-
labeled DNA (10 ng) was incubated with increasing concentrations (0,
5, 10, 20, 40, and 80 mM) of DOC prior to electrophoresis. 
, no
DOC. (B) EMSA analysis showing the disruption of the BreR-DNA
complex in the presence of DOC but not glycodeoxycholate (GDOC)
or glycocholate (Gchol). EMSA was performed with the R1 fragment
and 0 or 25 ng of BreR-His6 (lanes 
 to Gchol). DIG-dUTP-labeled
DNA (10 ng) was incubated with no bile salts (
), 10 mM DOC, 10
mM GDOC, or 10 mM Gchol.
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of genes associated with transcriptional regulation, vexR and
breR (see Table S1 in the supplemental material).
Since it has been shown previously that the expression of
genes that encode components of RND efflux pumps are in-
ducible by the various substrates extruded by the pumps (32,
36, 37, 46, 50), we analyzed the expression of vexAB and breAB
in the presence of various compounds. In doing so, we estab-
lished that crude bile, SDS, and novobiocin induced the ex-
pression of the vexAB genes but that the induction of the
expression of breAB was specific to bile, suggesting that this
operon responded exclusively to bile, unlike vexAB, which re-
sponded to several molecular signals. We therefore pursued
the study of the breAB regulatory mechanism.
Genes encoding components of RND efflux systems are
tightly regulated by regulators of the TetR family (30). We
showed that BreR, a TetR-like regulator, repressed breAB
expression, while VexR, another TetR regulator, did not affect
breAB expression. It was also demonstrated that BreR, as other
TetR members, was able to repress the expression of its own
gene. VexR does not repress or activate the breR promoter to
indirectly affect breAB expression since PbreAB-lacZ expression
was not affected in the vexR strain. -Galactosidase assays
demonstrated that a PbreAB-lacZ fusion exhibited high-level
expression in the presence of crude bile; however, in a breR
strain, the expression was even greater regardless of the pres-
ence of bile. Usually, local regulators play a modulating role,
while the principal transcriptional expression is controlled by
global regulators (13). These data support the hypothesis that
BreR functions as a repressor of the breAB operon by acting as
a local modulator preventing the excessive production of the
BreAB efflux pump and that VexR is neither a global nor a
local regulator of the breAB promoter. In addition, they
strongly suggest that there is no global activator that regulates
the expression of the breAB operon, such as the global activa-
tors MarA, SoxS, and Rob that induce the expression of the
genes encoding the AcrAB efflux system in E. coli (13). More-
over, since the -galactosidase assays indicated that the level of
expression of breAB was highest in the breR mutant, it is pos-
sible that a breR strain may be more resistant to bile than the
wild-type strain. MBC experiments with the wild-type and
breR strains determined that there was a 1.5-fold increase in
the resistance of a breR mutant to bile compared to that of the
wild type (data not shown), as may be expected.
EMSA confirmed that BreR directly binds to the breAB
promoter region at two independent sites, one (AB1 fragment)
proximal to and one (AB2 or AB2s fragment) distal from the
transcriptional start site. The finding that BreR completely
shifted the AB1 fragment at a level (250 ng) that produced only
a fractional shift of the AB2 or the AB2s fragment may indi-
cate that the affinity for the distal site is lower. Finally, the
results presented here indicate that BreR is able to repress the
expression of its corresponding gene and interacts directly with
the breR promoter region at a single site.
It is known that a number of regulators belonging to the
TetR family act as transcriptional repressors by binding to
their own operator sequences in the absence of effector/in-
ducer molecules. Once the effector enters the cell, it will bind
to a nonconserved domain on the C terminus of the repressor
and cause a conformational change resulting in the dissocia-
tion of the repressor from the DNA and the transcription of
the negatively regulated genes (45). Figure 9A shows that of all
the bile salts tested, cholate, deoxycholate, and chenodeoxy-
cholate, induce the expression of the PbreAB-lacZ and PbreR-
lacZ transcriptional fusions, suggesting that these bile salts can
serve as an environmental signal(s) necessary for the activation
of breAB and breR expression. In addition, MBC tests showed
that BreB mediates resistance to these bile salts (data not
shown). Previous studies with C. jejuni demonstrated that
CmeR, a TetR repressor, binds to the cmeABC promoter and
represses its expression (31). When bile is incubated with the
CmeR-cmeRAB complex, it interacts with CmeR, causing it to
dissociate from the promoter region (32). In V. cholerae, VceR,
a TetR family repressor of the vceAB operon, dissociates from
its operator sequence in the presence of 77.2 mM deoxycholate
(6). The findings of these studies demonstrate that bile or bile
salts can act as effectors/inducers of TetR family regulators.
We performed EMSA using deoxycholate, glycocholate, or
glycodeoxycholate, which demonstrated that deoxycholate, at
10 mM, specifically disrupted the binding of BreR to the breR
promoter. Similar results have been observed previously with
MarR, an S. enterica serovar Typhimurium transcriptional reg-
ulator belonging to the MarR family (42). MarR represses the
marRAB operon, which is involved in decreasing OmpF porin
levels and increasing AcrAB-TolC levels to reduce the influx
and enhance the efflux of antibiotic compounds, respectively
(30). Most importantly, it has been shown previously that de-
oxycholate specifically induces marR expression, and gel shift
experiments have demonstrated that this bile salt specifically
interacts with MarR, disrupting binding to the marRAB operon
(42) in parallel to the interaction with BreR described here.
Based on the results that show (i) breAB and breR induction
by cholate, deoxycholate, and chenodeoxycholate and (ii) the
inhibition of BreR binding to the breR promoter by deoxy-
cholate, as well as the data in the supporting literature, we
propose a model wherein BreR is continuously associated with
the breR and breAB promoters, repressing their expression.
Once cholate, deoxycholate, and/or chenodeoxycholate enters
the cell, it binds to BreR, causing the dissociation of the BreR-
DNA complex, resulting in breR and breAB expression.
It has been demonstrated previously that the tetracycline
repressor (TetR) binds to the tetA operator in the absence of
tetracycline (an effector/inducer molecule), repressing the ex-
pression of tetA, which encodes an efflux pump, and that the
tetR gene is expressed simultaneously with the tetA gene. This
synchronized expression ensures that there is enough repressor
available to inactivate the expression of tetA when tetracycline
has been completely secreted out of the cell (18). Our results
show that breR and breAB share this feature since both PbreR-
lacZ and PbreAB-lacZ showed higher levels of expression in the
presence of bile, specifically in the presence of cholate, deoxy-
cholate, and chenodeoxycholate, than in the absence of bile.
Finally, the organization of breR with respect to breAB rep-
resents a novel arrangement for these systems, since the genes
that encode TetR regulators that control the expression of the
cognate genes encoding RND efflux systems are localized
either in a divergent orientation adjacent to the genes they reg-
ulate (1, 17, 31, 35) or in the same operon (39, 53). In contrast,
breR is located 8.99 kb upstream, positioned several genes
away from the breAB operon. Genes encoding hypothetical
proteins, paraquat-inducible protein A and B, and a putative
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lipoprotein are among the genes between breR and the breAB
operon. Interestingly, three of the genes encoding hypothetical
proteins were also identified in our microarray study as being
induced in the presence of bile (see Table S1 in the supple-
mental material). These genes are currently under investiga-
tion.
The findings reported here demonstrate that BreR is the
transcriptional repressor of the breAB efflux system operon and
that this repression is probably accomplished by binding at two
independent binding sites in the breAB promoter. In addition,
BreR negatively regulates its own expression by binding to one
site at the breR promoter. The mechanism of BreR repression
at these promoters is currently under investigation. Lastly, we
propose that BreR requires an effector/inducer molecule(s) to
dissociate from the breAB and/or breR promoter and that the
effector/inducer molecule(s) may be cholate, deoxycholate,
and/or chenodeoxycholate.
ACKNOWLEDGMENTS
We thank Karen Skorupski for helpful discussions and critical read-
ing of the manuscript and Gabriela Kovacikova for technical assis-
tance.
This work was supported by NIH grant AI039654 and NSF grant
OCN-0120677.
REFERENCES
1. Aires, J. R., T. Kohler, H. Nikaido, and P. Plesiat. 1999. Involvement of an
active efflux system in the natural resistance of Pseudomonas aeruginosa to
aminoglycosides. Antimicrob. Agents Chemother. 43:2624–2628.
2. Begley, M., C. G. Gahan, and C. Hill. 2005. The interaction between bacteria
and bile. FEMS Microbiol. Rev. 29:625–651.
3. Bina, J. E., and J. J. Mekalanos. 2001. Vibrio cholerae tolC is required for bile
resistance and colonization. Infect. Immun. 69:4681–4685.
4. Bina, J. E., D. Provenzano, C. Wang, X. R. Bina, and J. J. Mekalanos. 2006.
Characterization of the Vibrio cholerae vexAB and vexCD efflux systems.
Arch. Microbiol. 186:171–181.
5. Blanco, C., M. Mata-Gilsinger, and P. Ritzenthaler. 1985. The use of gene
fusions to study the expression of uidR, a negative regulatory gene of Esch-
erichia coli K-12. Gene 36:159–167.
6. Borges-Walmsley, M. I., D. Du, K. S. McKeegan, G. J. Sharples, and A. R.
Walmsley. 2005. VceR regulates the vceCAB drug efflux pump operon of
Vibrio cholerae by alternating between mutually exclusive conformations that
bind either drugs or promoter DNA. J. Mol. Biol. 349:387–400.
7. Chatterjee, A., S. Chaudhuri, G. Saha, S. Gupta, and R. Chowdhury. 2004.
Effect of bile on the cell surface permeability barrier and efflux system of
Vibrio cholerae. J. Bacteriol. 186:6809–6814.
8. Colmer, J. A., J. A. Fralick, and A. N. Hamood. 1998. Isolation and charac-
terization of a putative multidrug resistance pump from Vibrio cholerae. Mol.
Microbiol. 27:63–72.
9. Folcher, M., R. P. Morris, G. Dale, K. Salah-Bey-Hocini, P. H. Viollier, and
C. J. Thompson. 2001. A transcriptional regulator of a pristinamycin resis-
tance gene in Streptomyces coelicolor. J. Biol. Chem. 276:1479–1485.
10. Fralick, J. A. 1996. Evidence that TolC is required for functioning of the
Mar/AcrAB efflux pump of Escherichia coli. J. Bacteriol. 178:5803–5805.
11. Frohman, M. A., M. K. Dush, and G. R. Martin. 1988. Rapid production of
full-length cDNAs from rare transcripts: amplification using a single gene-
specific oligonucleotide primer. Proc. Natl. Acad. Sci. USA 85:8998–9002.
12. Grkovic, S., M. H. Brown, N. J. Roberts, I. T. Paulsen, and R. A. Skurray.
1998. QacR is a repressor protein that regulates expression of the Staphylo-
coccus aureus multidrug efflux pump QacA. J. Biol. Chem. 273:18665–18673.
13. Grkovic, S., M. H. Brown, and R. A. Skurray. 2002. Regulation of bacterial
drug export systems. Microbiol. Mol. Biol. Rev. 66:671–701.
14. Gunn, J. S. 2000. Mechanisms of bacterial resistance and response to bile.
Microbes Infect. 2:907–913.
15. Gupta, S., and R. Chowdhury. 1997. Bile affects production of virulence
factors and motility of Vibrio cholerae. Infect. Immun. 65:1131–1134.
16. Guzman, L. M., D. Belin, M. J. Carson, and J. Beckwith. 1995. Tight regu-
lation, modulation, and high-level expression by vectors containing the
arabinose PBAD promoter. J. Bacteriol. 177:4121–4130.
17. Hagman, K. E., and W. M. Shafer. 1995. Transcriptional control of the mtr
efflux system of Neisseria gonorrhoeae. J. Bacteriol. 177:4162–4165.
18. Hillen, W., C. Gatz, L. Altschmied, K. Schollmeier, and I. Meier. 1983.
Control of expression of the Tn10-encoded tetracycline resistance genes.
Equilibrium and kinetic investigation of the regulatory reactions. J. Mol.
Biol. 169:707–721.
19. Hinrichs, W., C. Kisker, M. Duvel, A. Muller, K. Tovar, W. Hillen, and W.
Saenger. 1994. Structure of the Tet repressor-tetracycline complex and reg-
ulation of antibiotic resistance. Science 264:418–420.
20. Hofmann, A. F. 1998. Bile secretion and the enterohepatic circulation of bile
salts, 6th ed. W. B. Saunders, Philadelphia, PA.
21. Hung, D. T., E. A. Shakhnovich, E. Pierson, and J. J. Mekalanos. 2005.
Small-molecule inhibitor of Vibrio cholerae virulence and intestinal coloni-
zation. Science 310:670–674.
22. Hung, D. T., J. Zhu, D. Sturtevant, and J. J. Mekalanos. 2006. Bile acids
stimulate biofilm formation in Vibrio cholerae. Mol. Microbiol. 59:193–201.
23. Iwanaga, M., K. Yamamoto, N. Higa, Y. Ichinose, N. Nakasone, and M.
Tanabe. 1986. Culture conditions for stimulating cholera toxin production by
Vibrio cholerae O1 El Tor. Microbiol. Immunol. 30:1075–1083.
24. Kovacikova, G., W. Lin, and K. Skorupski. 2005. Dual regulation of genes
involved in acetoin biosynthesis and motility/biofilm formation by the viru-
lence activator AphA and the acetate-responsive LysR-type regulator AlsR
in Vibrio cholerae. Mol. Microbiol. 57:420–433.
25. Kovacikova, G., W. Lin, and K. Skorupski. 2003. The virulence activator
AphA links quorum sensing to pathogenesis and physiology in Vibrio chol-
erae by repressing the expression of a penicillin amidase gene on the small
chromosome. J. Bacteriol. 185:4825–4836.
26. Kovacikova, G., and K. Skorupski. 2001. Overlapping binding sites for the
virulence gene regulators AphA, AphB and cAMP-CRP at the Vibrio chol-
erae tcpPH promoter. Mol. Microbiol. 41:393–407.
27. Kovacikova, G., and K. Skorupski. 2002. Regulation of virulence gene ex-
pression in Vibrio cholerae by quorum sensing: HapR functions at the aphA
promoter. Mol. Microbiol. 46:1135–1147.
28. Kovacikova, G., and K. Skorupski. 1999. A Vibrio cholerae LysR homolog,
AphB, cooperates with AphA at the tcpPH promoter to activate expression
of the ToxR virulence cascade. J. Bacteriol. 181:4250–4256.
29. Lacroix, F. J., A. Cloeckaert, O. Grepinet, C. Pinault, M. Y. Popoff, H.
Waxin, and P. Pardon. 1996. Salmonella typhimurium acrB-like gene: iden-
tification and role in resistance to biliary salts and detergents and in murine
infection. FEMS Microbiol. Lett. 135:161–167.
30. Li, X. Z., and H. Nikaido. 2004. Efflux-mediated drug resistance in bacteria.
Drugs 64:159–204.
31. Lin, J., M. Akiba, O. Sahin, and Q. Zhang. 2005. CmeR functions as a
transcriptional repressor for the multidrug efflux pump CmeABC in Campy-
lobacter jejuni. Antimicrob. Agents Chemother. 49:1067–1075.
32. Lin, J., C. Cagliero, B. Guo, Y. W. Barton, M. C. Maurel, S. Payot, and Q.
Zhang. 2005. Bile salts modulate expression of the CmeABC multidrug efflux
pump in Campylobacter jejuni. J. Bacteriol. 187:7417–7424.
33. Lin, J., L. O. Michel, and Q. Zhang. 2002. CmeABC functions as a multidrug
efflux system in Campylobacter jejuni. Antimicrob. Agents Chemother. 46:
2124–2131.
34. Lin, J., O. Sahin, L. O. Michel, and Q. Zhang. 2003. Critical role of multi-
drug efflux pump CmeABC in bile resistance and in vivo colonization of
Campylobacter jejuni. Infect. Immun. 71:4250–4259.
35. Ma, D., M. Alberti, C. Lynch, H. Nikaido, and J. E. Hearst. 1996. The local
repressor AcrR plays a modulating role in the regulation of acrAB genes of
Escherichia coli by global stress signals. Mol. Microbiol. 19:101–112.
36. Ma, D., D. N. Cook, M. Alberti, N. G. Pon, H. Nikaido, and J. E. Hearst.
1995. Genes acrA and acrB encode a stress-induced efflux system of Esche-
richia coli. Mol. Microbiol. 16:45–55.
37. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino.
2000. Contribution of the MexX-MexY-OprM efflux system to intrinsic re-
sistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:
2242–2246.
38. Miller, J. H. 1972. Experiments in molecular genetics. Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY.
39. Namwat, W., C. K. Lee, H. Kinoshita, Y. Yamada, and T. Nihira. 2001.
Identification of the varR gene as a transcriptional regulator of virginiamycin
S resistance in Streptomyces virginiae. J. Bacteriol. 183:2025–2031.
40. Parsot, C., and J. J. Mekalanos. 1990. Expression of ToxR, the transcrip-
tional activator of the virulence factors in Vibrio cholerae, is modulated by the
heat shock response. Proc. Natl. Acad. Sci. USA 87:9898–9902.
41. Poole, K., K. Tetro, Q. Zhao, S. Neshat, D. E. Heinrichs, and N. Bianco.
1996. Expression of the multidrug resistance operon mexA-mexB-oprM in
Pseudomonas aeruginosa: mexR encodes a regulator of operon expression.
Antimicrob. Agents Chemother. 40:2021–2028.
42. Prouty, A. M., I. E. Brodsky, S. Falkow, and J. S. Gunn. 2004. Bile-salt-
mediated induction of antimicrobial and bile resistance in Salmonella typhi-
murium. Microbiology 150:775–783.
43. Provenzano, D., and K. E. Klose. 2000. Altered expression of the ToxR-
regulated porins OmpU and OmpT diminishes Vibrio cholerae bile resis-
tance, virulence factor expression, and intestinal colonization. Proc. Natl.
Acad. Sci. USA 97:10220–10224.
44. Provenzano, D., D. A. Schuhmacher, J. L. Barker, and K. E. Klose. 2000. The
virulence regulatory protein ToxR mediates enhanced bile resistance in
VOL. 190, 2008 breAB REGULATION BY BreR 7451
Vibrio cholerae and other pathogenic Vibrio species. Infect. Immun. 68:1491–
1497.
45. Ramos, J. L., M. Martinez-Bueno, A. J. Molina-Henares, W. Teran, K.
Watanabe, X. Zhang, M. T. Gallegos, R. Brennan, and R. Tobes. 2005. The
TetR family of transcriptional repressors. Microbiol. Mol. Biol. Rev. 69:326–
356.
46. Rouquette, C., J. B. Harmon, and W. M. Shafer. 1999. Induction of the
mtrCDE-encoded efflux pump system of Neisseria gonorrhoeae requires
MtrA, an AraC-like protein. Mol. Microbiol. 33:651–658.
47. Sandu, C., C. B. Chiribau, and R. Brandsch. 2003. Characterization of
HdnoR, the transcriptional repressor of the 6-hydroxy-D-nicotine oxidase
gene of Arthrobacter nicotinovorans pAO1, and its DNA-binding activity in
response to L- and D-nicotine derivatives. J. Biol. Chem. 278:51307–51315.
48. Schuhmacher, D. A., and K. E. Klose. 1999. Environmental signals modulate
ToxT-dependent virulence factor expression in Vibrio cholerae. J. Bacteriol.
181:1508–1514.
49. Skorupski, K., and R. K. Taylor. 1996. Positive selection vectors for allelic
exchange. Gene 169:47–52.
50. Teran, W., A. Felipe, A. Segura, A. Rojas, J. L. Ramos, and M. T. Gallegos.
2003. Antibiotic-dependent induction of Pseudomonas putida DOT-T1E
TtgABC efflux pump is mediated by the drug binding repressor TtgR. An-
timicrob. Agents Chemother. 47:3067–3072.
51. Teran, W., T. Krell, J. L. Ramos, and M. T. Gallegos. 2006. Effector-repressor
interactions, binding of a single effector molecule to the operator-bound TtgR
homodimer mediates derepression. J. Biol. Chem. 281:7102–7109.
52. Touze, T., J. Eswaran, E. Bokma, E. Koronakis, C. Hughes, and V.
Koronakis. 2004. Interactions underlying assembly of the Escherichia coli
AcrAB-TolC multidrug efflux system. Mol. Microbiol. 53:697–706.
53. Yoshida, K., Y. H. Ohki, M. Murata, M. Kinehara, H. Matsuoka, T. Satomura,
R. Ohki, M. Kumano, K. Yamane, and Y. Fujita. 2004. Bacillus subtilis LmrA is
a repressor of the lmrAB and yxaGH operons: identification of its binding site
and functional analysis of lmrB and yxaGH. J. Bacteriol. 186:5640–5648.
7452 CERDA-MAIRA ET AL. J. BACTERIOL.
